| Diffuse large B-cell lymphoma (DLBCL) is the most commonnon-Hodgkin lymphoma and accounts for about30%-40%of all non-Hodgkinlymphoma. DLBCL is composed of different subtypes， and patients exhibit awide range of clinical presentation and prognoses. In recent years, researchersuse immunological and molecular techniques to classify tumors and to developappropriate treatment strategies. Now cell surface antigens are relatively easyto access, and tumor origins and clinical features are more easily identifiable.However, the clinical significance of tumor surface antigens in DLBCL has notbeen well documented. Of the several surface antigens selected for flowcytometric analysis, the importance of the dendritic cell maker CD21in thegeneration of DLBCL are recognized and become significant biological factors.Only few reports on this have been published abroad while there is no definiteones in our country. As a result，We explored the expression of the dendriticcell maker CD21in DLBCL and its clinical significance in this article.Objective: To analyze CD21expression in diffuse large B cell lymphoma(DLBCL)and to explore its relationship with the clinicopathological character-ristics and prognosis．Methods: The clinical data from80DLBCL patients who were treated inFirst Bethune Hospital of Jilin University from June2005to September2011were retrospectively analyzed，and has been applied immunohistochemistry (SP)staining detected Ki-67, CD20, CD79a and CD3, CD43, CD5, Cyclin D1,Bcl-2, CDl0, Bcl-6, GCET-1, FOXP-1andMUM-1protein expression of thetumor tissue. Immunohistochemistry (SP) staining was also used to detect theexpression of CD21of the tumor tissue. Application SPSS18.0to analyze the data, analysis the relationship between the expression of CD21and variousclinical factors, and analysis the relationship between various clinical factorsincluding CD21and overall survival time.Results: In the patients aged under60years，the incidence of CD21+lymphoma(64.0%，16/25)was significantly higher than that of CD21-ones(38.2%，21/55)；CD21+patients with clinical stage I～II（52.0%，13/25）were significantly higher than that of CD21-ones(23.6%，13/55)；Less than twoextranodal involvements in CD21+patients(68.0%，17/25)were more comm.-only found than that of CD21-patients (41.8％，23/55)；CD21+patients with IPI0～2（68.0%，17/25）were significantly higher than that of CD21-ones(41.8%，23/55)； CD21+patients with the GCB sub-type （60.0%，15/25） weresignificantly higher than that of CD21-ones(23.6%，13/55)； DLBCL-relateddeath in CD21+patients(32.0%，8/25)was lower than that of CD21-patients(56.4％，31/55)．Univariate analysis showed that over the clinicalpathological characteristic affect the overall survival of DLBCL patients，Age、ECOG score、LDH、extranodal involvement、IPI index、CD21expression、treatment options and efficacy are closely related to prognosis, and thedifference was statistically significant（P<0.05）. COX multivariate analysisshowed that ECOG score, LDH, extranodal involvement, CD21expression areclosely related to prognosis, and the difference was statistically significant（P<0.05）. And over the80patients，the overall survival(OS) of CD21+patients were significantly higher than those of CD21-patients．In the conditionof different GCB type，different IPI and therapy，the OS of CD21+DLBCLpatients was significantly higher than that of CD21-patients．Conclusions:1.The expression of CD21had the characteristics of low ageat onset, early clinical stage, small number of involvement and small IPI index. 2. The overall survival(OS) and the median overall survival of CD21+patientswere significantly higher than those of CD21-patients．3. CD21expression,ECOG score, LDH, extranodal involvement are independent prognostic factorsin DLBCL, in particular, the expression of CD21is more significant to theprognosis of DLBCL patients.4. The stratified analysis showed that DLBCLpatients with GCB subtype, higher IPI index and using CHOP chemotherapy,the expression of CD21had more predictive value on the prognosis. |
PDF Full Text Request